Endogenex Raises $50M To Advance ReCET Diabetes Trial
Plymouth-based Endogenex raised $50M to expand clinical testing of its ReCET endoscopic therapy for type 2 diabetes; pivotal trial readouts expected in late 2026.
JD
jordan de la cruz
via Hoodline
Updated 1h ago

Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
In Space, No One Can Hear You Switch Tasks
Next
Topological soliton frequency comb in nanophotonic lithium niobate - Nature
Related Articles
ScienceThursday Essay: Here Comes Skynet
Stephen Green-2h ago-1 sources
ScienceNorthland block struggles to heal from ‘shared trauma’ of years-long feud, killing
Eric Adler,Laura Bauer-2h ago-1 sources
ScienceTrump appoints Nvidia's Jensen Huang, AMD's Lisa Su, Meta's Mark Zuckerberg, and more to science and technology advisory committee
Jacob Fox-2h ago-1 sources